Blood Stream Infection Testing Market By Product (Instruments, Consumables, Software and Services), By Technique (Conventional, Automated), By Technology (Culture-based, Molecular, Proteomic), By Application (Bacterial, Fungal, Mycobacterial), By End-users (Hospitals, Independent Diagnostics Centers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2030
The global blood stream infection testing market was valued at $10,540.8 million by 2030, and is anticipated to reach $5,173.1 million in 2021, growing at a CAGR of 8.3% from 2022 to 2030.
A blood stream infection is any bacterial, fungal, or other type of infection that is discovered in the blood. As soon as the infection enters the bloodstream of any part of the body, the illness becomes evident. . Testing for blood stream infections is done to find out which bacteria or other organisms are responsible for the blood infections. The ongoing population growth and worsening of sanitary conditions pose a serious threat to human health since they encourage the spread of various infectious illnesses. Due to the vast range of symptoms associated with bloodstream infections, including chills, cold, fever, diarrhea, and vomiting, self-diagnosis can be difficult. The BSI is concern for patient due to high morbidity and mortality rates. According to WHO It is estimated 49 million people and causes 11 million deaths globally every year. For detection and diagnosis of the infection, the in-vitro diagnostic techniques (blood cultures) are widely used. In the microbiology laboratory, technological developments in molecular approaches have transformed the approach of diagnosing microbial infections. As theses sophisticated technologies have become faster, more automated, and easier to use, they have become essential part of routine testing and repertoire in most diagnostic laboratories.
As technology develops and automated systems such as MALDI-TOF and DOT are developed, high cost of ownership and high maintenance expenses are projected to hinder the market growth. Also, costly testing techniques may make them unaffordable and this is projected to hamper the blood stream infection testing market trend. Market expansion can be constrained due to lack of insurance and reimbursement regulations.
The increase in the number of sepsis and bacteremia globally is expected to drive the blood stream infection testing market. Bacteremia and sepsis are few of the top causes of mortality rate in United States, causing over 600 fatalities each day. The need for rapid diagnosis and recent advancement in bloodstream infection testing are expected to boost the market growth. The increasing incidences of bloodstream infection in elderly population who are susceptible to infection due to low immunity is anticipate to drive the demand for blood stream infection testing market growth.
The COVID-19 epidemic in 2020 adversely affected the world's economy and triggered a public health calamity on a worldwide scale. However, the COVID-19 had a positive effect on the market for testing for blood stream infections worldwide.
Blood culture is the gold standard for identifying an illness or pathogen, thus in pandemic BSI testing has seen a sharp rise in popularity. The incidence rate of blood stream infection in COVID-19 patients was discovered to be 0.863% compared to patients without COVID having 0.437%. The rise in instances in North America and Europe accelerated the expansion of blood stream testing market. The need for infections or microorganisms to be diagnosed increased significantly.
The major key players in the global blood stream infection testing market are Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Abbott, BD, BIOMÉRIEUX, Cepheid, Luminex Corporation, Accelerate Diagnostics Inc., AdvanDX, and Bruker.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the blood stream infection testing market analysis from 2021 to 2030 to identify the prevailing blood stream infection testing market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the blood stream infection testing market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global blood stream infection testing market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
Instrument
Consumables
Software & Services
By Technique
Conventional
Automated
By technology
Culture-based
Molecular
Proteomic
By Application
Bacterial
Fungal
Mycobacterial
By End-user
Hospitals
Independent Diagnostics Centers
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
United Arab Emirates
South Africa
Rest of LAMEA
Key Market Segments
By Technology
Culture-based
Molecular
Proteomic
By Product
Instruments
Consumables
Software and Services
By Technique
Conventional
Automated
By Application
Bacterial
Fungal
Mycobacterial
By End-users
Hospitals
Independent Diagnostics Centers
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
United Arab Emirates
South Africa
Rest of LAMEA
Key Market Players
Thermo Fisher Scientific, Inc.
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
becton dickinson medical devices co. ltd., suzhou
bioMérieux SA
cepheid
Luminex Corporation
Accelerate Diagnostics Inc.
AdvanDx
Bruker Corporation
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- 3.7.Value Chain Analysis
- 3.8.Market Share Analysis
- 3.9.Regulatory Guidelines
- 3.10.Key Regulation Analysis
- 3.11.Patent Landscape
- CHAPTER 4: BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Instruments
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Consumables
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Software and Services
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- CHAPTER 5: BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Conventional
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Automated
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- CHAPTER 6: BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Culture-based
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Molecular
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Proteomic
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- CHAPTER 7: BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 Bacterial
- 7.2.1 Key market trends, growth factors and opportunities
- 7.2.2 Market size and forecast, by region
- 7.2.3 Market analysis by country
- 7.3 Fungal
- 7.3.1 Key market trends, growth factors and opportunities
- 7.3.2 Market size and forecast, by region
- 7.3.3 Market analysis by country
- 7.4 Mycobacterial
- 7.4.1 Key market trends, growth factors and opportunities
- 7.4.2 Market size and forecast, by region
- 7.4.3 Market analysis by country
- CHAPTER 8: BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS
- 8.1 Overview
- 8.1.1 Market size and forecast
- 8.2 Hospitals
- 8.2.1 Key market trends, growth factors and opportunities
- 8.2.2 Market size and forecast, by region
- 8.2.3 Market analysis by country
- 8.3 Independent Diagnostics Centers
- 8.3.1 Key market trends, growth factors and opportunities
- 8.3.2 Market size and forecast, by region
- 8.3.3 Market analysis by country
- 8.4 Others
- 8.4.1 Key market trends, growth factors and opportunities
- 8.4.2 Market size and forecast, by region
- 8.4.3 Market analysis by country
- CHAPTER 9: BLOOD STREAM INFECTION TESTING MARKET, BY REGION
- 9.1 Overview
- 9.1.1 Market size and forecast
- 9.2 North America
- 9.2.1 Key trends and opportunities
- 9.2.2 North America Market size and forecast, by Product
- 9.2.3 North America Market size and forecast, by Technique
- 9.2.4 North America Market size and forecast, by Technology
- 9.2.5 North America Market size and forecast, by Application
- 9.2.6 North America Market size and forecast, by End-users
- 9.2.7 North America Market size and forecast, by country
- 9.2.7.1 U.S.
- 9.2.7.1.1 Market size and forecast, by Product
- 9.2.7.1.2 Market size and forecast, by Technique
- 9.2.7.1.3 Market size and forecast, by Technology
- 9.2.7.1.4 Market size and forecast, by Application
- 9.2.7.1.5 Market size and forecast, by End-users
- 9.2.7.2 Canada
- 9.2.7.2.1 Market size and forecast, by Product
- 9.2.7.2.2 Market size and forecast, by Technique
- 9.2.7.2.3 Market size and forecast, by Technology
- 9.2.7.2.4 Market size and forecast, by Application
- 9.2.7.2.5 Market size and forecast, by End-users
- 9.2.7.3 Mexico
- 9.2.7.3.1 Market size and forecast, by Product
- 9.2.7.3.2 Market size and forecast, by Technique
- 9.2.7.3.3 Market size and forecast, by Technology
- 9.2.7.3.4 Market size and forecast, by Application
- 9.2.7.3.5 Market size and forecast, by End-users
- 9.3 Europe
- 9.3.1 Key trends and opportunities
- 9.3.2 Europe Market size and forecast, by Product
- 9.3.3 Europe Market size and forecast, by Technique
- 9.3.4 Europe Market size and forecast, by Technology
- 9.3.5 Europe Market size and forecast, by Application
- 9.3.6 Europe Market size and forecast, by End-users
- 9.3.7 Europe Market size and forecast, by country
- 9.3.7.1 Germany
- 9.3.7.1.1 Market size and forecast, by Product
- 9.3.7.1.2 Market size and forecast, by Technique
- 9.3.7.1.3 Market size and forecast, by Technology
- 9.3.7.1.4 Market size and forecast, by Application
- 9.3.7.1.5 Market size and forecast, by End-users
- 9.3.7.2 United Kingdom
- 9.3.7.2.1 Market size and forecast, by Product
- 9.3.7.2.2 Market size and forecast, by Technique
- 9.3.7.2.3 Market size and forecast, by Technology
- 9.3.7.2.4 Market size and forecast, by Application
- 9.3.7.2.5 Market size and forecast, by End-users
- 9.3.7.3 France
- 9.3.7.3.1 Market size and forecast, by Product
- 9.3.7.3.2 Market size and forecast, by Technique
- 9.3.7.3.3 Market size and forecast, by Technology
- 9.3.7.3.4 Market size and forecast, by Application
- 9.3.7.3.5 Market size and forecast, by End-users
- 9.3.7.4 Spain
- 9.3.7.4.1 Market size and forecast, by Product
- 9.3.7.4.2 Market size and forecast, by Technique
- 9.3.7.4.3 Market size and forecast, by Technology
- 9.3.7.4.4 Market size and forecast, by Application
- 9.3.7.4.5 Market size and forecast, by End-users
- 9.3.7.5 Italy
- 9.3.7.5.1 Market size and forecast, by Product
- 9.3.7.5.2 Market size and forecast, by Technique
- 9.3.7.5.3 Market size and forecast, by Technology
- 9.3.7.5.4 Market size and forecast, by Application
- 9.3.7.5.5 Market size and forecast, by End-users
- 9.3.7.6 Rest of Europe
- 9.3.7.6.1 Market size and forecast, by Product
- 9.3.7.6.2 Market size and forecast, by Technique
- 9.3.7.6.3 Market size and forecast, by Technology
- 9.3.7.6.4 Market size and forecast, by Application
- 9.3.7.6.5 Market size and forecast, by End-users
- 9.4 Asia-Pacific
- 9.4.1 Key trends and opportunities
- 9.4.2 Asia-Pacific Market size and forecast, by Product
- 9.4.3 Asia-Pacific Market size and forecast, by Technique
- 9.4.4 Asia-Pacific Market size and forecast, by Technology
- 9.4.5 Asia-Pacific Market size and forecast, by Application
- 9.4.6 Asia-Pacific Market size and forecast, by End-users
- 9.4.7 Asia-Pacific Market size and forecast, by country
- 9.4.7.1 China
- 9.4.7.1.1 Market size and forecast, by Product
- 9.4.7.1.2 Market size and forecast, by Technique
- 9.4.7.1.3 Market size and forecast, by Technology
- 9.4.7.1.4 Market size and forecast, by Application
- 9.4.7.1.5 Market size and forecast, by End-users
- 9.4.7.2 Japan
- 9.4.7.2.1 Market size and forecast, by Product
- 9.4.7.2.2 Market size and forecast, by Technique
- 9.4.7.2.3 Market size and forecast, by Technology
- 9.4.7.2.4 Market size and forecast, by Application
- 9.4.7.2.5 Market size and forecast, by End-users
- 9.4.7.3 India
- 9.4.7.3.1 Market size and forecast, by Product
- 9.4.7.3.2 Market size and forecast, by Technique
- 9.4.7.3.3 Market size and forecast, by Technology
- 9.4.7.3.4 Market size and forecast, by Application
- 9.4.7.3.5 Market size and forecast, by End-users
- 9.4.7.4 South Korea
- 9.4.7.4.1 Market size and forecast, by Product
- 9.4.7.4.2 Market size and forecast, by Technique
- 9.4.7.4.3 Market size and forecast, by Technology
- 9.4.7.4.4 Market size and forecast, by Application
- 9.4.7.4.5 Market size and forecast, by End-users
- 9.4.7.5 Australia
- 9.4.7.5.1 Market size and forecast, by Product
- 9.4.7.5.2 Market size and forecast, by Technique
- 9.4.7.5.3 Market size and forecast, by Technology
- 9.4.7.5.4 Market size and forecast, by Application
- 9.4.7.5.5 Market size and forecast, by End-users
- 9.4.7.6 Rest of Asia-Pacific
- 9.4.7.6.1 Market size and forecast, by Product
- 9.4.7.6.2 Market size and forecast, by Technique
- 9.4.7.6.3 Market size and forecast, by Technology
- 9.4.7.6.4 Market size and forecast, by Application
- 9.4.7.6.5 Market size and forecast, by End-users
- 9.5 LAMEA
- 9.5.1 Key trends and opportunities
- 9.5.2 LAMEA Market size and forecast, by Product
- 9.5.3 LAMEA Market size and forecast, by Technique
- 9.5.4 LAMEA Market size and forecast, by Technology
- 9.5.5 LAMEA Market size and forecast, by Application
- 9.5.6 LAMEA Market size and forecast, by End-users
- 9.5.7 LAMEA Market size and forecast, by country
- 9.5.7.1 Brazil
- 9.5.7.1.1 Market size and forecast, by Product
- 9.5.7.1.2 Market size and forecast, by Technique
- 9.5.7.1.3 Market size and forecast, by Technology
- 9.5.7.1.4 Market size and forecast, by Application
- 9.5.7.1.5 Market size and forecast, by End-users
- 9.5.7.2 Saudi Arabia
- 9.5.7.2.1 Market size and forecast, by Product
- 9.5.7.2.2 Market size and forecast, by Technique
- 9.5.7.2.3 Market size and forecast, by Technology
- 9.5.7.2.4 Market size and forecast, by Application
- 9.5.7.2.5 Market size and forecast, by End-users
- 9.5.7.3 United Arab Emirates
- 9.5.7.3.1 Market size and forecast, by Product
- 9.5.7.3.2 Market size and forecast, by Technique
- 9.5.7.3.3 Market size and forecast, by Technology
- 9.5.7.3.4 Market size and forecast, by Application
- 9.5.7.3.5 Market size and forecast, by End-users
- 9.5.7.4 South Africa
- 9.5.7.4.1 Market size and forecast, by Product
- 9.5.7.4.2 Market size and forecast, by Technique
- 9.5.7.4.3 Market size and forecast, by Technology
- 9.5.7.4.4 Market size and forecast, by Application
- 9.5.7.4.5 Market size and forecast, by End-users
- 9.5.7.5 Rest of LAMEA
- 9.5.7.5.1 Market size and forecast, by Product
- 9.5.7.5.2 Market size and forecast, by Technique
- 9.5.7.5.3 Market size and forecast, by Technology
- 9.5.7.5.4 Market size and forecast, by Application
- 9.5.7.5.5 Market size and forecast, by End-users
- CHAPTER 10: COMPANY LANDSCAPE
- 10.1. Introduction
- 10.2. Top winning strategies
- 10.3. Product Mapping of Top 10 Player
- 10.4. Competitive Dashboard
- 10.5. Competitive Heatmap
- 10.6. Key developments
- CHAPTER 11: COMPANY PROFILES
- 11.1 Thermo Fisher Scientific, Inc.
- 11.1.1 Company overview
- 11.1.2 Company snapshot
- 11.1.3 Operating business segments
- 11.1.4 Product portfolio
- 11.1.5 Business performance
- 11.1.6 Key strategic moves and developments
- 11.2 F. Hoffmann-La Roche Ltd.
- 11.2.1 Company overview
- 11.2.2 Company snapshot
- 11.2.3 Operating business segments
- 11.2.4 Product portfolio
- 11.2.5 Business performance
- 11.2.6 Key strategic moves and developments
- 11.3 Abbott Laboratories
- 11.3.1 Company overview
- 11.3.2 Company snapshot
- 11.3.3 Operating business segments
- 11.3.4 Product portfolio
- 11.3.5 Business performance
- 11.3.6 Key strategic moves and developments
- 11.4 becton dickinson medical devices co. ltd., suzhou
- 11.4.1 Company overview
- 11.4.2 Company snapshot
- 11.4.3 Operating business segments
- 11.4.4 Product portfolio
- 11.4.5 Business performance
- 11.4.6 Key strategic moves and developments
- 11.5 bioMérieux SA
- 11.5.1 Company overview
- 11.5.2 Company snapshot
- 11.5.3 Operating business segments
- 11.5.4 Product portfolio
- 11.5.5 Business performance
- 11.5.6 Key strategic moves and developments
- 11.6 cepheid
- 11.6.1 Company overview
- 11.6.2 Company snapshot
- 11.6.3 Operating business segments
- 11.6.4 Product portfolio
- 11.6.5 Business performance
- 11.6.6 Key strategic moves and developments
- 11.7 Luminex Corporation
- 11.7.1 Company overview
- 11.7.2 Company snapshot
- 11.7.3 Operating business segments
- 11.7.4 Product portfolio
- 11.7.5 Business performance
- 11.7.6 Key strategic moves and developments
- 11.8 Accelerate Diagnostics Inc.
- 11.8.1 Company overview
- 11.8.2 Company snapshot
- 11.8.3 Operating business segments
- 11.8.4 Product portfolio
- 11.8.5 Business performance
- 11.8.6 Key strategic moves and developments
- 11.9 AdvanDx
- 11.9.1 Company overview
- 11.9.2 Company snapshot
- 11.9.3 Operating business segments
- 11.9.4 Product portfolio
- 11.9.5 Business performance
- 11.9.6 Key strategic moves and developments
- 11.10 Bruker Corporation
- 11.10.1 Company overview
- 11.10.2 Company snapshot
- 11.10.3 Operating business segments
- 11.10.4 Product portfolio
- 11.10.5 Business performance
- 11.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 2. BLOOD STREAM INFECTION TESTING MARKET REVENUE, FOR INSTRUMENTS, BY REGION , 2021-2030,($MILLION)
- TABLE 3. BLOOD STREAM INFECTION TESTING MARKET FOR INSTRUMENTS BY COUNTRY, 2021-2030,($MILLION)
- TABLE 4. BLOOD STREAM INFECTION TESTING MARKET REVENUE, FOR CONSUMABLES, BY REGION , 2021-2030,($MILLION)
- TABLE 5. BLOOD STREAM INFECTION TESTING MARKET FOR CONSUMABLES BY COUNTRY, 2021-2030,($MILLION)
- TABLE 6. BLOOD STREAM INFECTION TESTING MARKET REVENUE, FOR SOFTWARE AND SERVICES, BY REGION , 2021-2030,($MILLION)
- TABLE 7. BLOOD STREAM INFECTION TESTING MARKET FOR SOFTWARE AND SERVICES BY COUNTRY, 2021-2030,($MILLION)
- TABLE 8. GLOBAL BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 9. BLOOD STREAM INFECTION TESTING MARKET REVENUE, FOR CONVENTIONAL, BY REGION , 2021-2030,($MILLION)
- TABLE 10. BLOOD STREAM INFECTION TESTING MARKET FOR CONVENTIONAL BY COUNTRY, 2021-2030,($MILLION)
- TABLE 11. BLOOD STREAM INFECTION TESTING MARKET REVENUE, FOR AUTOMATED, BY REGION , 2021-2030,($MILLION)
- TABLE 12. BLOOD STREAM INFECTION TESTING MARKET FOR AUTOMATED BY COUNTRY, 2021-2030,($MILLION)
- TABLE 13. GLOBAL BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 14. BLOOD STREAM INFECTION TESTING MARKET REVENUE, FOR CULTURE-BASED, BY REGION , 2021-2030,($MILLION)
- TABLE 15. BLOOD STREAM INFECTION TESTING MARKET FOR CULTURE-BASED BY COUNTRY, 2021-2030,($MILLION)
- TABLE 16. BLOOD STREAM INFECTION TESTING MARKET REVENUE, FOR MOLECULAR, BY REGION , 2021-2030,($MILLION)
- TABLE 17. BLOOD STREAM INFECTION TESTING MARKET FOR MOLECULAR BY COUNTRY, 2021-2030,($MILLION)
- TABLE 18. BLOOD STREAM INFECTION TESTING MARKET REVENUE, FOR PROTEOMIC, BY REGION , 2021-2030,($MILLION)
- TABLE 19. BLOOD STREAM INFECTION TESTING MARKET FOR PROTEOMIC BY COUNTRY, 2021-2030,($MILLION)
- TABLE 20. GLOBAL BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 21. BLOOD STREAM INFECTION TESTING MARKET REVENUE, FOR BACTERIAL, BY REGION , 2021-2030,($MILLION)
- TABLE 22. BLOOD STREAM INFECTION TESTING MARKET FOR BACTERIAL BY COUNTRY, 2021-2030,($MILLION)
- TABLE 23. BLOOD STREAM INFECTION TESTING MARKET REVENUE, FOR FUNGAL, BY REGION , 2021-2030,($MILLION)
- TABLE 24. BLOOD STREAM INFECTION TESTING MARKET FOR FUNGAL BY COUNTRY, 2021-2030,($MILLION)
- TABLE 25. BLOOD STREAM INFECTION TESTING MARKET REVENUE, FOR MYCOBACTERIAL, BY REGION , 2021-2030,($MILLION)
- TABLE 26. BLOOD STREAM INFECTION TESTING MARKET FOR MYCOBACTERIAL BY COUNTRY, 2021-2030,($MILLION)
- TABLE 27. GLOBAL BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 28. BLOOD STREAM INFECTION TESTING MARKET REVENUE, FOR HOSPITALS, BY REGION , 2021-2030,($MILLION)
- TABLE 29. BLOOD STREAM INFECTION TESTING MARKET FOR HOSPITALS BY COUNTRY, 2021-2030,($MILLION)
- TABLE 30. BLOOD STREAM INFECTION TESTING MARKET REVENUE, FOR INDEPENDENT DIAGNOSTICS CENTERS, BY REGION , 2021-2030,($MILLION)
- TABLE 31. BLOOD STREAM INFECTION TESTING MARKET FOR INDEPENDENT DIAGNOSTICS CENTERS BY COUNTRY, 2021-2030,($MILLION)
- TABLE 32. BLOOD STREAM INFECTION TESTING MARKET REVENUE, FOR OTHERS, BY REGION , 2021-2030,($MILLION)
- TABLE 33. BLOOD STREAM INFECTION TESTING MARKET FOR OTHERS BY COUNTRY, 2021-2030,($MILLION)
- TABLE 34. BLOOD STREAM INFECTION TESTING MARKET, BY REGION, 2021-2030,($MILLION)
- TABLE 35. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 36. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 37. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 38. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 39. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 40. NORTH AMERICA BLOOD STREAM INFECTION TESTING MARKET, BY COUNTRY, 2021-2030,($MILLION)
- TABLE 41. U.S. BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 42. U.S. BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 43. U.S. BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 44. U.S. BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 45. U.S. BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 46. CANADA BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 47. CANADA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 48. CANADA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 49. CANADA BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 50. CANADA BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 51. MEXICO BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 52. MEXICO BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 53. MEXICO BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 54. MEXICO BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 55. MEXICO BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 56. EUROPE BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 57. EUROPE BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 58. EUROPE BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 59. EUROPE BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 60. EUROPE BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 61. EUROPE BLOOD STREAM INFECTION TESTING MARKET, BY COUNTRY, 2021-2030,($MILLION)
- TABLE 62. GERMANY BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 63. GERMANY BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 64. GERMANY BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 65. GERMANY BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 66. GERMANY BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 67. UNITED KINGDOM BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 68. UNITED KINGDOM BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 69. UNITED KINGDOM BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 70. UNITED KINGDOM BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 71. UNITED KINGDOM BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 72. FRANCE BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 73. FRANCE BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 74. FRANCE BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 75. FRANCE BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 76. FRANCE BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 77. SPAIN BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 78. SPAIN BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 79. SPAIN BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 80. SPAIN BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 81. SPAIN BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 82. ITALY BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 83. ITALY BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 84. ITALY BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 85. ITALY BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 86. ITALY BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 87. REST OF EUROPE BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 88. REST OF EUROPE BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 89. REST OF EUROPE BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 90. REST OF EUROPE BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 91. REST OF EUROPE BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 92. ASIA-PACIFIC BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 93. ASIA-PACIFIC BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 94. ASIA-PACIFIC BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 95. ASIA-PACIFIC BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 96. ASIA-PACIFIC BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 97. ASIA-PACIFIC BLOOD STREAM INFECTION TESTING MARKET, BY COUNTRY, 2021-2030,($MILLION)
- TABLE 98. CHINA BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 99. CHINA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 100. CHINA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 101. CHINA BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 102. CHINA BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 103. JAPAN BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 104. JAPAN BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 105. JAPAN BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 106. JAPAN BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 107. JAPAN BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 108. INDIA BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 109. INDIA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 110. INDIA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 111. INDIA BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 112. INDIA BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 113. SOUTH KOREA BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 114. SOUTH KOREA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 115. SOUTH KOREA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 116. SOUTH KOREA BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 117. SOUTH KOREA BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 118. AUSTRALIA BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 119. AUSTRALIA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 120. AUSTRALIA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 121. AUSTRALIA BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 122. AUSTRALIA BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 123. REST OF ASIA-PACIFIC BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 124. REST OF ASIA-PACIFIC BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 125. REST OF ASIA-PACIFIC BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 126. REST OF ASIA-PACIFIC BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 127. REST OF ASIA-PACIFIC BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 128. LAMEA BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 129. LAMEA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 130. LAMEA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 131. LAMEA BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 132. LAMEA BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 133. LAMEA BLOOD STREAM INFECTION TESTING MARKET, BY COUNTRY, 2021-2030,($MILLION)
- TABLE 134. BRAZIL BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 135. BRAZIL BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 136. BRAZIL BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 137. BRAZIL BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 138. BRAZIL BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 139. SAUDI ARABIA BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 140. SAUDI ARABIA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 141. SAUDI ARABIA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 142. SAUDI ARABIA BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 143. SAUDI ARABIA BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 144. UNITED ARAB EMIRATES BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 145. UNITED ARAB EMIRATES BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 146. UNITED ARAB EMIRATES BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 147. UNITED ARAB EMIRATES BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 148. UNITED ARAB EMIRATES BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 149. SOUTH AFRICA BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 150. SOUTH AFRICA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 151. SOUTH AFRICA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 152. SOUTH AFRICA BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 153. SOUTH AFRICA BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 154. REST OF LAMEA BLOOD STREAM INFECTION TESTING MARKET, BY PRODUCT, 2021-2030,($MILLION)
- TABLE 155. REST OF LAMEA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNIQUE, 2021-2030,($MILLION)
- TABLE 156. REST OF LAMEA BLOOD STREAM INFECTION TESTING MARKET, BY TECHNOLOGY, 2021-2030,($MILLION)
- TABLE 157. REST OF LAMEA BLOOD STREAM INFECTION TESTING MARKET, BY APPLICATION, 2021-2030,($MILLION)
- TABLE 158. REST OF LAMEA BLOOD STREAM INFECTION TESTING MARKET, BY END-USERS, 2021-2030,($MILLION)
- TABLE 159.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
- TABLE 160.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
- TABLE 161.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
- TABLE 162.THERMO FISHER SCIENTIFIC, INC.: NET SALES,
- TABLE 163.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES
- TABLE 164.F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
- TABLE 165.F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
- TABLE 166.F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
- TABLE 167.F. HOFFMANN-LA ROCHE LTD.: NET SALES,
- TABLE 168.F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
- TABLE 169.ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 170.ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 171.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 172.ABBOTT LABORATORIES: NET SALES,
- TABLE 173.ABBOTT LABORATORIES: KEY STRATERGIES
- TABLE 174.BECTON DICKINSON MEDICAL DEVICES CO. LTD., SUZHOU: COMPANY SNAPSHOT
- TABLE 175.BECTON DICKINSON MEDICA
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook